Epidemiology
British Journal of Cancer (2008) 98, 989–991. doi:10.1038/sj.bjc.6604240 www.bjcancer.com
Published online 12 February 2008
Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial
S M Zhang1, N R Cook1,2, J E Manson1,2,3, I-M Lee1,2 and J E Buring1,2,4
- 1Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 2Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
- 3Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 4Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA, USA
Correspondence: Dr SM Zhang, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA. E-mail: shumin.zhang@channing.harvard.edu
Received 5 November 2007; Revised 11 January 2008; Accepted 11 January 2008; Published online 12 February 2008.
Abstract
The Women's Health Study trial previously reported no overall effect of low-dose aspirin (100 mg every other day) on invasive breast cancer over an average of 10 years of treatment. The present subgroup analyses further show no effects by tumour characteristics at diagnosis, suggesting that low-dose aspirin has no preventive effect on breast cancer.
Keywords:
aspirin, breast cancer, incidence
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Do-it-yourself guide: how to use the modern single-molecule toolkit
Nature Methods Review (01 Jun 2008)
